Sebastian Kobold

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5082645/publications.pdf

Version: 2024-02-01

104	5,177	117625	102487
papers	citations	34	66
		h-index	g-index

113	113	113	7964
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Advances in cancer immunotherapy 2019 â€“ latest trends. Journal of Experimental and Clinical Cancer Research, 2019, 38, 268.	8.6	401
2	Antibody-mediated inhibition of MICA and MICB shedding promotes NK cellâ€“driven tumor immunity. Science, 2018, 359, 1537-1542.	12.6	323
3	Interleukins in cancer: from biology to therapy. Nature Reviews Cancer, 2021, 21, 481-499.	28.4	318
4	Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells. International Journal of Molecular Sciences, 2019, 20, 1283.	4.1	296
5	Teaching an old dog new tricks: next-generation CAR T cells. British Journal of Cancer, 2019, 120, 26-37.	6.4	240
6	CXCR6 positions cytotoxic TÂcells to receive critical survival signals in the tumor microenvironment. Cell, 2021, 184, 4512-4530.e22.	28.9	180
7	RIG-I-like helicases induce immunogenic cell death of pancreatic cancer cells and sensitize tumors toward killing by CD8+ T cells. Cell Death and Differentiation, 2014, 21, 1825-1837.	11.2	151
8	Epithelial-type systemic breast carcinoma cells with a restricted mesenchymal transition are a major source of metastasis. Science Advances, 2019, 5, eaav4275.	10.3	139
9	Toll-Like Receptor 4â€“Induced IL-22 Accelerates Kidney Regeneration. Journal of the American Society of Nephrology: JASN, 2014, 25, 978-989.	6.1	122
10	Limitations in the Design of Chimeric Antigen Receptors for Cancer Therapy. Cells, 2019, 8, 472.	4.1	122
11	Cancer cells induce interleukin-22 production from memory CD4⁺T cells via interleukin-1 to promote tumor growth. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 12994-12999.	7.1	115
12	Enhancing tumor T cell infiltration to enable cancer immunotherapy. Immunotherapy, 2019, 11, 201-213.	2.0	108
13	Inflammation: a common contributor to cancer, aging, and cardiovascular diseasesâ€”expanding the concept of cardio-oncology. Cardiovascular Research, 2019, 115, 824-829.	3.8	101
14	Impact of a New Fusion Receptor on PD-1â€“Mediated Immunosuppression in Adoptive T Cell Therapy. Journal of the National Cancer Institute, 2015, 107, .	6.3	96
15	Intraperitoneal VEGF Inhibition Using Bevacizumab: A Potential Approach for the Symptomatic Treatment of Malignant Ascites?. Oncologist, 2009, 14, 1242-1251.	3.7	91
16	Endogenous TCR promotes in vivo persistence of CD19-CAR-T cells compared to a CRISPR/Cas9-mediated TCR knockout CAR. Blood, 2020, 136, 1407-1418.	1.4	91
17	Melanoma models for the next generation of therapies. Cancer Cell, 2021, 39, 610-631.	16.8	90
18	Rationale for Combining Bispecific T Cell Activating Antibodies With Checkpoint Blockade for Cancer Therapy. Frontiers in Oncology, 2018, 8, 285.	2.8	89

#	Article	IF	Citations
19	Cancer-testis antigens MAGE-C1/CT7 and MAGE-A3 promote the survival of multiple myeloma cells. Haematologica, 2010, 95, 785-793.	3.5	87
20	T cells armed with C-X-C chemokine receptor type 6 enhance adoptive cell therapy for pancreatic tumours. Nature Biomedical Engineering, 2021, 5, 1246-1260.	22.5	80
21	Bifunctional PD-1 Ã— Î±CD3 Ã— Î±CD33 fusion protein reverses adaptive immune escape in acute myeloid leukemia. Blood, 2018, 132, 2484-2494.	1.4	73
22	The cytokine/chemokine pattern in the bone marrow environment of multiple myeloma patients. Experimental Hematology, 2010, 38, 860-867.	0.4	72
23	Modes of action of TLR7 agonists in cancer therapy. Immunotherapy, 2014, 6, 1085-1095.	2.0	66
24	Interleukin-22 Is Frequently Expressed in Small- and Large-Cell Lung Cancer and Promotes Growth in Chemotherapy-Resistant Cancer Cells. Journal of Thoracic Oncology, 2013, 8, 1032-1042.	1.1	62
25	Determinants of response and resistance to CAR T cell therapy. Seminars in Cancer Biology, 2020, 65, 80-90.	9.6	59
26	C-C chemokine receptor type-4 transduction of T cells enhances interaction with dendritic cells, tumor infiltration and therapeutic efficacy of adoptive T cell transfer. OncoImmunology, 2016, 5, e1105428.	4.6	58
27	Combined tumor-directed recruitment and protection from immune suppression enable CAR T cell efficacy in solid tumors. Science Advances, 2021, 7, .	10.3	56
28	Surface molecule CD229 as a novel target for the diagnosis and treatment of multiple myeloma. Haematologica, 2011, 96, 1512-1520.	3.5	52
29	Utilizing chemokines in cancer immunotherapy. Trends in Cancer, 2022, 8, 670-682.	7.4	50
30	Attenuation of peripheral serotonin inhibits tumor growth and enhances immune checkpoint blockade therapy in murine tumor models. Science Translational Medicine, 2021, 13, eabc8188.	12.4	48
31	Autoantibodies against tumor-related antigens: Incidence and biologic significance. Human Immunology, 2010, 71, 643-651.	2.4	47
32	An optimized assay for the enumeration of antigen-specific memory B cells in different compartments of the human body. Journal of Immunological Methods, 2010, 358, 56-65.	1.4	46
33	Comparison of Intranasal Outer Membrane Vesicles with Cholera Toxin and Injected MF59C.1 as Adjuvants for Malaria Transmission Blocking Antigens AnAPN1 and Pfs48/45. Journal of Immunology Research, 2016, 2016, 1-11.	2.2	45
34	Protease-activation using anti-idiotypic masks enables tumor specificity of a folate receptor 1-T cell bispecific antibody. Nature Communications, 2020, 11, 3196.	12.8	43
35	CXCR6 deficiency impairs cancer vaccine efficacy and CD8⁺ resident memory T-cell recruitment in head and neck and lung tumors. , 2021, 9, e001948.		41
36	Combining the best of two worlds: highly flexible chimeric antigen receptor adaptor molecules (CAR-adaptors) for the recruitment of chimeric antigen receptor T cells. MAbs, 2019, 11, 621-631.	5.2	38

#	Article	IF	Citations
37	Targeting interleukin-22 for cancer therapy. Human Vaccines and Immunotherapeutics, 2018, 14, 2012-2015.	3.3	37
38	Targeted activation of melanoma differentiation-associated protein 5 (MDA5) for immunotherapy of pancreatic carcinoma. OncoImmunology, 2015, 4, e1029698.	4.6	36
39	High-affinity CD16-polymorphism and Fc-engineered antibodies enable activity of CD16-chimeric antigen receptor-modified T cells for cancer therapy. British Journal of Cancer, 2019, 120, 79-87.	6.4	36
40	Selective Bispecific T Cell Recruiting Antibody and Antitumor Activity of Adoptive T Cell Transfer. Journal of the National Cancer Institute, 2015, 107, 364.	6.3	34
41	Therapeutic Strategies for Targeting IL-1 in Cancer. Cancers, 2021, 13, 477.	3.7	34
42	Expression, epigenetic regulation, and humoral immunogenicity of cancer-testis antigens in chronic myeloid leukemia. Leukemia Research, 2010, 34, 1647-1655.	0.8	33
43	RIG-I-based immunotherapy enhances survival in preclinical AML models and sensitizes AML cells to checkpoint blockade. Leukemia, 2020, 34, 1017-1026.	7.2	33
44	Immunotherapy in Tumors. Deutsches Ärzteblatt International, 2015, 112, 809-15.	0.9	31
45	Bispecific Antibodies Enable Synthetic Agonistic Receptor-Transduced T Cells for Tumor Immunotherapy. Clinical Cancer Research, 2019, 25, 5890-5900.	7.0	31
46	Strategies to relieve immunosuppression in pancreatic cancer. Immunotherapy, 2015, 7, 363-376.	2.0	30
47	Microphthalmia-Associated Transcription Factor (MITF) Regulates Immune Cell Migration into Melanoma. Translational Oncology, 2019, 12, 350-360.	3.7	27
48	Broad T Cell Targeting of Structural Proteins After SARS-CoV-2 Infection: High Throughput Assessment of T Cell Reactivity Using an Automated Interferon Gamma Release Assay. Frontiers in Immunology, 2021, 12, 688436.	4.8	26
49	Long non-coding RNAs in cancer stem cells. Translational Oncology, 2021, 14, 101134.	3.7	25
50	Lung emphysema and impaired macrophage elastase clearance in mucolipin 3 deficient mice. Nature Communications, 2022, 13, 318.	12.8	25
51	Prognostic and Diagnostic Value of Spontaneous Tumor-Related Antibodies. Clinical and Developmental Immunology, 2010, 2010, 1-8.	3.3	24
52	PD1-CD28 Fusion Protein Enables CD4+ T Cell Help for Adoptive T Cell Therapy in Models of Pancreatic Cancer and Non-hodgkin Lymphoma. Frontiers in Immunology, 2018, 9, 1955.	4.8	24
53	A modular and controllable T cell therapy platform for acute myeloid leukemia. Leukemia, 2021, 35, 2243-2257.	7.2	24
54	Using Antigen-Specific B Cells to Combine Antibody and T Cellâ€“Based Cancer Immunotherapy. Cancer Immunology Research, 2017, 5, 730-743.	3.4	23

#	Article	IF	Citations
55	Skin dendritic cells in melanoma are key for successful checkpoint blockade therapy. , 2021, 9, e000832.		23
56	TetraMabs: simultaneous targeting of four oncogenic receptor tyrosine kinases for tumor growth inhibition in heterogeneous tumor cell populations. Protein Engineering, Design and Selection, 2016, 29, 467-475.	2.1	22
57	A novel TLR7 agonist reverses NK cell anergy and cures RMA-S lymphoma-bearing mice. OncoImmunology, 2016, 5, e1189051.	4.6	22
58	Immunostimulatory RNA leads to functional reprogramming of myeloid-derived suppressor cells in pancreatic cancer. , 2019, 7, 288.		22
59	Nlrp3-dependent IL-1Î² inhibits CD103+ dendritic cell differentiation in the gut. JCI Insight, 2018, 3, .	5.0	22
60	Activated SUMOylation restricts MHC class I antigen presentation to confer immune evasion in cancer. Journal of Clinical Investigation, 2022, 132, .	8.2	22
61	The macrophage migration inhibitory factor (MIF)-homologue D-dopachrome tautomerase is a therapeutic target in a murine melanoma model. Oncotarget, 2014, 5, 103-107.	1.8	20
62	Interleukin-22 is elevated in lavage from patients with lung cancer and other pulmonary diseases. BMC Cancer, 2016, 16, 409.	2.6	19
63	Can we use interleukin-1Î² blockade for lung cancer treatment?. Translational Lung Cancer Research, 2018, 7, S160-S164.	2.8	19
64	Dual-targeting triplebody 33-3-19 mediates selective lysis of biphenotypic CD19+ CD33+ leukemia cells. Oncotarget, 2016, 7, 22579-22589.	1.8	19
65	Functional autoantibodies against SSX-2 and NY-ESO-1 in multiple myeloma patients after allogeneic stem cell transplantation. Cancer Immunology, Immunotherapy, 2014, 63, 1151-1162.	4.2	17
66	IL-22 sustains epithelial integrity in progressive kidney remodeling and fibrosis. Physiological Reports, 2018, 6, e13817.	1.7	17
67	CAR TÂcell therapy in solid tumors: aÂshort review. Memo - Magazine of European Medical Oncology, 2021, 14, 143-149.	0.5	17
68	Augmenting anti-CD19 and anti-CD22 CAR T-cell function using PD-1-CD28 checkpoint fusion proteins. Blood Cancer Journal, 2021, 11, 108.	6.2	17
69	NK Cells Armed with Chimeric Antigen Receptors (CAR): Roadblocks to Successful Development. Cells, 2021, 10, 3390.	4.1	17
70	Isolated Limb Perfusion with Melphalan for the Treatment of Intractable Primary Cutaneous Diffuse Large B-Cell Lymphoma Leg Type. Acta Haematologica, 2010, 123, 179-181.	1.4	16
71	Defective Interfering Genomes and the Full-Length Viral Genome Trigger RIG-I After Infection With Vesicular Stomatitis Virus in a Replication Dependent Manner. Frontiers in Immunology, 2021, 12, 595390.	4.8	16
72	Dying cells expose a nuclear antigen cross-reacting with anti-PD-1 monoclonal antibodies. Scientific Reports, 2018, 8, 8810.	3.3	13

#	Article	IF	Citations
73	Prolonged time to treatment initiation in advanced pancreatic cancer patients has no major effect on treatment outcome: a retrospective cohort study controlled for lead time bias and waiting time paradox. Journal of Cancer Research and Clinical Oncology, 2020, 146, 391-399.	2.5	13
74	Paralysis of the cytotoxic granule machinery is a new cancer immune evasion mechanism mediated by chitinase 3-like-1. , 2021, 9, e003224.		12
75	Novel systemic treatment approaches for metastatic pancreatic cancer. Expert Opinion on Investigational Drugs, 2022, 31, 249-262.	4.1	12
76	Cryptic Epitopes Induce High-Titer Humoral Immune Response in Patients with Cancer. Journal of Immunology, 2010, 185, 3095-3102.	0.8	10
77	Interleukin-37 Inhibits Colon Carcinogensis During Chronic Colitis. Frontiers in Immunology, 2019, 10, 2632.	4.8	10
78	The Neurokinin-1 Receptor Is a Target in Pediatric Rhabdoid Tumors. Current Oncology, 2022, 29, 94-110.	2.2	10
79	CAR T Cells Targeting Membrane-Bound Hsp70 on Tumor Cells Mimic Hsp70-Primed NK Cells. Frontiers in Immunology, 2022, 13, .	4.8	10
80	Patients with Multiple Myeloma Develop SOX2-Specific Autoantibodies after Allogeneic Stem Cell Transplantation. Clinical and Developmental Immunology, 2011, 2011, 1-10.	3.3	9
81	Longitudinal Analysis of Tetanus- and Influenza-Specific IgG Antibodies in Myeloma Patients. Clinical and Developmental Immunology, 2012, 2012, 1-9.	3.3	9
82	Challenges in Clinical Trial Design for T Cellâ€Based Cancer Immunotherapy. Clinical Pharmacology and Therapeutics, 2020, 107, 47-49.	4.7	9
83	Enhanced Chimeric Antigen Receptor T Cell Therapy through Co-Application of Synergistic Combination Partners. Biomedicines, 2022, 10, 307.	3.2	9
84	Innate Immune Stimulation in Cancer Therapy. Hematology/Oncology Clinics of North America, 2019, 33, 215-231.	2.2	8
85	Enabling T Cell Recruitment to Tumours as a Strategy for Improving Adoptive T Cell Therapy. European Oncology and Haematology, 2017, 13, 66.	0.0	8
86	Design and Evaluation of TIM-3-CD28 Checkpoint Fusion Proteins to Improve Anti-CD19 CAR T-Cell Function. Frontiers in Immunology, 2022, 13, 845499.	4.8	8
87	Utility and Drawbacks of Chimeric Antigen Receptor T Cell (CAR-T) Therapy in Lung Cancer. Frontiers in Immunology, 0, 13, .	4.8	7
88	Virus-associated activation of innate immunity induces rapid disruption of Peyerâ€™s patches in mice. Blood, 2013, 122, 2591-2599.	1.4	6
89	P329G-CAR-J: a novel Jurkat-NFAT-based CAR-T reporter system recognizing the P329G Fc mutation. Protein Engineering, Design and Selection, 2019, 32, 207-218.	2.1	6
90	T cell-recruiting triplebody 19-3-19 mediates serial lysis of malignant B-lymphoid cells by a single T cell. Oncotarget, 2014, 5, 6466-6483.	1.8	6

#	Article	IF	Citations
91	Prodrug-Activating Chain Exchange (PACE) converts targeted prodrug derivatives to functional bi- or multispecific antibodies. Biological Chemistry, 2022, 403, 495-508.	2.5	6
92	Evolving role of cetuximab in the treatment of colorectal cancer. Cancer Management and Research, 2009, 1, 79-88.	1.9	5
93	Chimeric Antigen Receptorâ€“Modified T Cells and T Cellâ€“Engaging Bispecific Antibodies: Different Tools for the Same Job. Current Hematologic Malignancy Reports, 2021, 16, 218-233.	2.3	4
94	An In Vivo Inflammatory Loop Potentiates KRAS Blockade. Biomedicines, 2022, 10, 592.	3.2	4
95	Innate and adaptive immunity combined for cancer treatment. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 1087-1088.	7.1	3
96	ESCRT machinery: role of membrane repair mechanisms in escaping cell death. Signal Transduction and Targeted Therapy, 2022, 7, .	17.1	3
97	Flow cytometry detection and quantification of CAR T cells into solid tumors. Methods in Cell Biology, 2022, 167, 99-122.	1.1	2
98	FLT3 - ITD positive acute lymphocytic leukemia, does it impact on diseaseÂ´s course?. Turkish Journal of Haematology, 2010, 27, 133-134.	0.5	1
99	Interleukin-1Î² und pro-tumorale Inflammation â€“ Zentrale Faktoren bei der Entstehung von Krebserkrankungen. Oncology Research and Treatment, 2020, 43, 6-12.	1.2	1
100	Sixth Immunotherapy of Cancer conference (ITOC): advances and perspectivesâ€”a meeting report. , 2020, 8, e000268.		0
101	An In Sitro Assay to Predict Primary Resistance to PD-1 Blockade. Trends in Molecular Medicine, 2021, 27, 297-298.	6.7	0
102	Abstract 185: G-protein Coupled Receptor 55 Deficiency Promotes Atherosclerosis and Inflammation in Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, .	2.4	0
103	Neue Strategien fÃ¼r die onkologische Therapie: Interleukine im Fokus. , 0, , .		0
104	Abstract 570: Developing a novel adaptor CAR-T cell platform based on the recognition of the P329G Fc mutation in therapeutic IgG1 antibodies for adoptive T cell therapy. Cancer Research, 2022, 82, 570-570.	0.9	0